<DOC>
	<DOCNO>NCT02006589</DOCNO>
	<brief_summary>This open-label , randomize , single dose , two-way crossover study . Each subject participate treatment period receive single oral dos candesartan cilexetil ( GW615775 ) reference candesartan cilexetil ( ATACANDâ„¢ ) ; treatment period separate washout period least 7 day great 14 day . This study aim determine relative bioavailability 8mg test formulation tablet candesartan cilexetil ( GW615775 ) compare 8mg reference tablet candesartan cilexetil healthy adult subject . ATACAND register trademark AstraZeneca group company .</brief_summary>
	<brief_title>Bioavailability Study Candesartan Cilexetil 8mg Tablet Under Fasting Conditions</brief_title>
	<detailed_description />
	<mesh_term>Candesartan</mesh_term>
	<mesh_term>Candesartan cilexetil</mesh_term>
	<criteria>Male female age 18 65 year age inclusive , time signing informed consent . Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter ( ) is/are specifically list inclusion exclusion criterion , outside reference range population study may include Investigator consultation GSK Medical Monitor require agree document find unlikely introduce additional risk factor interfere study procedure . Body weight &gt; = 50kg body mass index within range 19 24.9 kilogram per square meter ( kg/m^2 ) ( inclusive ) . A female subject eligible participate : Nonchildbearing potential define premenopausal female document tubal ligation hysterectomy definition , `` document '' refers outcome investigator's/designee 's review subject 's medical history study eligibility , obtain via verbal interview subject subject 's medical record ; postmenopausal define 12 month spontaneous amenorrhea questionable case blood sample simultaneous follicle stimulate hormone ( FSH ) &gt; 40 milliinternational unit ( MIU ) per milliliter ( mL ) estradiol &lt; 40 pigogram per mL ( pg/mL ) ( &lt; 147 picomole per liter ) confirmatory . Females hormone replacement therapy ( HRT ) whose menopausal status doubt require use one contraception method protocol wish continue HRT study . Otherwise , must discontinue HRT allow confirmation postmenopausal status prior study enrollment . For form HRT , least 24 week elapse cessation therapy blood draw ; interval depend type dosage HRT . Following confirmation postmenopausal status , resume use HRT study without use contraceptive method ; Childbearing potential negative pregnancy test determine serum urine human chorionic gonadotropin ( hCG ) test screen prior dose Agrees use one contraception method list Protocol appropriate period time ( determined product label investigator ) prior start dose sufficiently minimize risk pregnancy point . Female subject must agree use contraception followup contact visit.or samesex partner , prefer usual lifestyle . Male subject female partner childbearing potential must agree use one contraception method list Protocol . This criterion must follow time first dose study medication followup contact visit . Capable give write informed consent , include compliance requirement restriction list consent form . Alanine transaminase , alkaline phosphatase bilirubin &lt; = 1.5x upper limit normal ( ULN ) ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Based single average correct QT interval ( QTc ) triplicate electrocardiogram ( ECGs ) obtain brief recording period : QT duration correct heart rate Fridericia 's formula ( QTcF ) &lt; 450 millisecond ( msec ) . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . History regular alcohol consumption within 6 month study define : An average weekly intake &gt; 21 unit male &gt; 14 unit female . One unit equivalent 8 gram alcohol : halfpint ( approximately 240 mL ) beer , 1 glass ( 125 mL ) wine 1 ( 25 mL ) measure spirit . History sensitivity heparin heparininduced thrombocytopenia . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Gastrointestinal disease gastrointestinal surgical history affect absorption investigational drug . Any subject systolic BP &lt; 95 millimeter mercury ( mmHg ) recent history postural symptoms A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen Urinary cotinine level indicative smoke history regular use tobacco nicotinecontaining product within 6 month prior screen . A positive prestudy drug/alcohol screen . A positive test Human immunodeficiency virus ( HIV ) antibody . Pregnant female determine positive serum hCG test screen prior dosing . Where participation study would result donation blood blood product excess 500 mL within 90 day period . Lactating female . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 90 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Candesartan cilexetil</keyword>
	<keyword>Healthy adult human subject</keyword>
</DOC>